Evidence map›Paper›PMID 42722888›Full record

ArticleNature medicine2026

A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial.

Jason Xu, Chunli Mei, Xin Guan, Rong Du, Bin Wu, Di Wu, Mengjiao Li, Jingna Li, You Song, Hua Su and 23 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Jason Xu *Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chunli Mei *Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xin Guan *Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rong Du *Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bin Wu *Department of Rheumatology and Immunology of the First People's Hospital of Jingzhou, Jingzhou, China.
Di WuDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mengjiao LiDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jingna LiDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
You SongDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hua SuDepartment of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoqi ChenDepartment of Rheumatology and Immunology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Qianyu GuoShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Hanyang CheniTabMed Ltd, Shanghai, China.
Jonathan H SussmanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3057-3550
Gregory M ChenPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shovik BandyopadhyayPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Vinodh PillaiDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7126-6226
Tobias V LanzDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7106-8801
Michaela LiedtkeDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Kenan OnelDepartments of Medicine and Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Tamiko R KatsumotoDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7978-0315
Kai TanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xiaoqiang YaniTabMed Ltd, Shanghai, China.
May ChienDivision of Hematology, Stanford University, Stanford, CA, USA.
Giselle SalmasiDivision of Hematology, Stanford University, Stanford, CA, USA.
Andreas KerschbaumerDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.
David T TeacheyPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Eric MeffreDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.
Vanessa E KennedyDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
William H RobinsonDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4385-704X
Anbin HuangDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Matthew C BakerDivision of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0002-1907
Qiubai LiDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. qiubaili@hust.edu.cn.ORCID http://orcid.org/0000-0001-7884-0745

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to a fraction of patients who might benefit. Bispecific T cell engagers (TCEs) offer a potent, off-the-shelf approach to deep B cell depletion; however, controlled clinical evaluation in rheumatic disease remains limited. Here we report results from the intravenous treatment arm of an ongoing, first-in-disease, phase 1 trial of A-319, a next-generation CD3×CD19 TCE, in 12 patients with active systemic lupus erythematosus (SLE) with 52 weeks of follow-up. Patients received A-319 (0.3-1.2 μg kg

Indexed as

Antibodies, BispecificAntigens, CD19CD3 ComplexLupus Erythematosus, SystemicAdultB-LymphocytesFemaleHumansMaleMiddle AgedT-LymphocytesAntibodies, BispecificAntigens, CD19CD19 molecule, humanCD3 Complex

Identifiers

PMID42722888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.